Pedro Barata, MD, MSc

Articles

Dr Voss Shares Highlights from the COSMIC-313 and LITESPARK-024 Trials

July 2nd 2024

Martin Voss, MD, discusses the subgroup analysis of the COSMIC-313 study, which investigated the combination of nivolumab, ipilimumab, with or without cabozantinib (nivo + ipi +/- cabo), focusing on the potential advantages this treatment approach may offer for patients with intermediate to high-risk renal cell carcinoma (RCC).

Dr Xu Reviews Data from the CLEAR Trial and Recent Analyses at ASCO 2024 - Lenvatinib + Pembrolizumab in Frontline Advanced RCC

July 2nd 2024

Wenxin (Vincent) Xu, MD, reviews recent analyses from the CLEAR study, which evaluated the combination of lenvatinib and pembrolizumab as a frontline treatment for advanced renal cell carcinoma (RCC).

Dr Wulff-Burchfield Reviews CheckMate 214 and CheckMate 9ER

June 25th 2024

The panelists examine the latest findings from the CheckMate 214 trial, which assessed the combination of nivolumab and ipilimumab (nivo + ipi) as a first-line treatment for advanced renal cell carcinoma, focusing on efficacy, safety, and quality of life outcomes.

Treatment Selection in the Frontline Setting of Advanced Clear Cell RCC

June 25th 2024

Dr. Pedro Barata, MD, MSc, provides an overview of advanced clear cell renal cell carcinoma (RCC), discussing its typical presentation, the role of systemic therapies, and summarizing the first-line treatment options available for this condition.

Dr Barata on the Critical Updates for the Treatment of Advanced RCC in 2023

November 27th 2023

Pedro Barata, MD, MSc, discusses the biggest clinical trial updates to emerge for the treatment of patients with advanced renal cell carcinoma from the 2023 International Kidney Cancer Symposium.

Dr Barata on Staying Up to Date With Evolving Treatment Approaches in Kidney Cancer

August 28th 2023

Pedro Barata, MD, MSc, discusses the importance of staying up to date with evolving treatment approaches in kidney cancer.

Dr Barata on Immunotherapy Treatment and the Gut Microbiome in Kidney Cancer

August 25th 2023

Pedro Barata, MD, MSc, discusses important considerations regarding the relationship between immunotherapy treatment and the gut microbiome when treating patients with kidney cancer.

Dr Barata on the Relationship Between the Microbiome and Immunotherapy in RCC

July 26th 2023

Pedro Barata, MD, MSc, discusses the relationship between the gut microbiome and treatment with immunotherapy in patients with renal cell carcinoma.

Dr. Barata sobre el Ensayo EMBARK en Pacientes con Cáncer de Próstata no Metastásico de alto Riesgo y Sensible a Hormonas.

June 26th 2023

Pedro Barata, MD, MSc, discusses the importance of the phase 3 EMBARK trial in patients with high-risk, nonmetastatic hormone-sensitive prostate cancer.

Dr. Barata sobre las Necesidades no Cubiertas de los Pacientes con Cáncer de Próstata

June 26th 2023

Pedro Barata, MD, MSc, discusses remaining unmet needs for patients with prostate cancer.

Clinical Pearls for Treating Advanced Renal Cell Carcinoma

April 14th 2023

Pedro Barata, MD, MSc, and Benjamin Garmezy, MD, close their discussion with clinical pearls for community oncologists treating patients with advanced RCC.

Advanced RCC Treatments Following Prior Immune Checkpoint Inhibitors

April 7th 2023

Drs Barata and Garmezy give detailed thoughts on treating patients with advanced RCC who have received prior immune checkpoint inhibitors.

TIVO-3 Trial: Tivozanib for Patients With Advanced RCC

April 7th 2023

A comprehensive overview of the TIVO-3 trial, which compared tivozanib with sorafenib in patients with advanced renal cell carcinoma.

Advanced RCC Treatment Options Post-Progression

March 31st 2023

Experts on renal cell carcinoma discuss post-progression treatment options for RCC.

Considerations in Advanced RCC Treatment Selection

March 31st 2023

Pedro Barata, MD, MSc, and Benjamin Garmezy, MD, outline factors taken into consideration when selecting advanced RCC treatments.

Front Line Trials in Advanced RCC

March 24th 2023

Renal cell carcinoma experts discuss clinical trials, evaluating immunotherapies and tyrosine kinase inhibitors in the front line setting of advanced RCC.

Patient Profile: A 67-Year-Old Man With Metastatic Clear Cell RCC

March 24th 2023

Benjamin Garmezy, MD, presents the case of a 67-year-old man diagnosed with advanced renal cell carcinoma.

Renal Cell Carcinoma Histology and Risk Stratification

March 17th 2023

Experts on renal cell carcinoma describe the RCC histologies and tools used for risk stratification.

Overview of Renal Cell Carcinoma

March 17th 2023

Pedro Barata, MD, MSc, and Benjamin Garmezy, MD, open the discussion with an overview of renal cell carcinoma.

Dr. Barata on the Evolving Treatment Landscape in Urothelial Cancer

September 26th 2022

Pedro C. Barata, MD, MSc, discusses the evolving treatment landscape of urothelial cancer.